Live Breaking News & Updates on Digestive Diseases Group

(2)
The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis
Patients treated with orally-administered, non-absorbable engineered carbon of controlled porosity was safe, tolerable and showed trends in improvements in a range of biomarkers of systemic inflammation
The mechanism of this effect is modulation of dysbiosis, gut inflammation and leaky gut that are characteristic of cirrhosis
Planning for pivotal trials to support approval in Europe is now under way
7
th January, 2021 - The
CARBALIVE Consortium( CARBALIVE or the Consortium ) is pleased to announce positive data from the Phase 2 equivalent randomised, double-blind clinical trial of Carbalive, a product candidate for the treatment of patients with decompensated cirrhosis. Carbalive is specifically designed to remove harmful bacterial toxins from the gut, reduce gut inflammation and its permeabilit ....

Rajiv Jalan , Amber Fennell , Universitario Ram , Agustin Albillos , Akaza Bioscience , Zenios Bioscience , Jane Macnaughtan , Kostenloser Wertpapierhandel , University College London , European Union Horizon , Liver Failure Group At University College London , Cajal Institute For Health , Digestive Diseases Group , Carbalive Consortium , Consilium Strategic Communications , European Foundation , Chronic Liver Failure , European Union , Professor Rajiv Jalan , Liver Failure Group , Founding Member , Project Coordinator , Hospital Universitario Ram , Universidad De Alcal , Cajal Institute , Takeda Pharmaceutical ,